Phase 1/2 Study of Mobocertinib in mNSCLC With EGFR Exon 20 Insertions: EXCLAIM and Platinum-Pretreated Patients Cohorts

February 19, 2021 | Jyoti D. Patel, MD, FASCO

Share on:

Jyoti D. Patel, MD, FASCO, presents slides from the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer (WCLC) from the phase 1/2 study of mobocertinib in non–small cell lung cancer (NSCLC) with EGFR exon 20 insertions.